Details
Table of Contents
Preface
Chapter 1
Role of Glutamate in Aggression
(Cedo D. Miljevic, Ana Munjiza, Dusica Lecic Tosevski, Institute of Mental health, Belgrade, Serbia, and others)
Chapter 2
Should we be Excited about Glutamate Dysregulation in the Etiology of ADHD? A Review of the Data
(S.R. Batten, G.A. Gerhardt, P.E.A. Glaser, Department of Anatomy & Neurobiology, University of Kentucky, KY, USA, and others)
Chapter 3
Metabotropic Glutamate Receptors in Addictive Disorders
(Jeremy Egnatios and M. Foster Olive, School of Medicine, University of California at San Diego, La Jolla, CA, USA, and others)
Chapter 4
Migraine and Glutamate – Modulators of Glutamatergic Signalling as Potential Treatments of Neuropsychiatric Disorders
(C.F.Gasparini, R.A. Smith, and L.R. Griffiths, Menzies Health Institute Queensland, Griffith University Gold Coast, Southport, QLD, Australia, and others)
Chapter 5
Obsessive-Compulsive Disorder
(Gyula Bokor, Peter D. Anderson, Staff Psychiatrist, Taunton State Hospital, Taunton, MA, USA, and others)
Chapter 6
The Glutamatergic System in Alzheimer’s Disease Pathology
(S. Kar and G.B. Baker, Department of Medicine (Division of Neurology) and Centre for Prions and Protein Folding Diseases and Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada)
Chapter 7
Neurotransmission in Schizophrenia
(Marc C. Debelle, Medical Director, Clinical Development in several Pharmaceutical Companies, Brussels, Belgium)
Index
Reviews
“Glutamate is the single most common excitatory neurotransmitter in the human CNS and profoundly impacts on a number of brain circuits implicated in the production of mental disorders. Alterations in glutamatergic signaling are at the core of these symptoms, and in addition to NMDA hypofunction, disturbances in feedback loops are also present. Dr. Pavlovic’s book provides an overview on these and other clinically relevant issues that will help readers think through their practical and research implications for treatment and drug development. Particularly compelling are chapters that cover a myriad of common and important disease states, including attention-deficit hyperactivity disorder, obsessive-compulsive disorder, Alzheimer’s disease, migraine headache, addictive disorders, and clinical concerns that are encountered across different disorders such as aggression.” – Leslie Citrome, MD, MPH, Clinical Professor of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY USA. Editor in Chief, International Journal of Clinical Practice, Wiley-Blackwell, Oxford, UK
“It is clear that the glutamatergic system plays a critical role in modulating brain circuits that regulate core symptom domains across a range of neuropsychiatric conditions. As such, experimental therapeutic approaches to glutamate signalling have assumed increasing importance in academic and industry approaches to CNS drug development, and this book is a invaluable resource to guide such development in our field.” – Eric Hollander, MD, Director – Autism and Obsessive Compulsive Spectrum Program,and Anxiety and Depression Program,Clinical Professor of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine and Montefiore Medical Center
“A large body of both preclinical and clinical data points to the important role of the glutamate system in neuropsychiatric disorders. This volume represents a timely assessment of the involvement of the glutamate system in a range of psychiatric disorders and the therapeutic potential of agents targeting this system.” – John Dunlop Vice President and Head, Neuroscience Innovative Medicines at AstraZeneca
Click here to read the book review by – Prakash Masand, MD, Chairman and CEO, Global Medical Education
Click here to read the book review by – Raimund Buller, MD, Vice President, Global Clinical Research Psychiatry, Lundbeck, France
Click here to read the book review by – George Garibaldi, MD, VP CNS Development, F. Hoffmann-La Roche
